文献速递血栓与止血

去糖基化抗体产前治疗抗CD36介导的重度FNAIT新型小鼠模型研究

Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model.
PubMed 文献 · Blood · 2021-01-01

研究建立抗CD36介导的胎儿/新生儿同种免疫性血小板减少症(FNAIT)小鼠模型,发现母体抗CD36抗体导致幼崽高死亡率(40.26%)和胎盘功能障碍。产前给予IVIG(1 g/kg)可降低胎儿死亡(12.70%),但延迟给药无效;去糖基化抗CD36多克隆抗体(5 mg/kg)显著降低胎儿死亡(5.26%),去糖基化单克隆抗体32-106效果更优(2.17%),且剂量更低、起始更晚。

要点

  • 母体抗CD36抗体可致幼崽高死亡率(40.26%)及胎盘血管生成缺陷。
  • 产前IVIG(1 g/kg)于第7、12、17天给药降低胎儿死亡至12.70%,延迟给药无效。
  • 去糖基化抗CD36单抗32-106(2.17%)优于多克隆抗体(5.26%),剂量更低且可晚启动。

核心结论

  • 母体抗CD36抗体在小鼠模型中导致高频胎儿死亡,与胎盘功能障碍相关。
  • 产前给予IVIG或去糖基化抗CD36抗体(多克隆或单克隆32-106)可减轻胎儿死亡。
  • 去糖基化单抗32-106在更低剂量、更晚起始治疗下仍显示更优疗效。

研究设计与样本

  • 建立新型动物模型:免疫Cd36-/-雌鼠与野生型雄鼠交配后观察幼崽临床特征。
  • 干预实验:比较IVIG不同给药方案及去糖基化抗CD36多克隆抗体、单克隆抗体32-106的效果。

主要发现

  • 免疫雌鼠幼崽出现轻度血小板减少,但死亡率高达40.26%。
  • IVIG(1 g/kg)于第7、12、17天给药使胎儿死亡降至12.70%;延迟至第10、15、20天给药未降低胎儿死亡(40.00%)。
  • 去糖基化抗CD36多克隆抗体(5 mg/kg)于第10、15、20天给药使胎儿死亡降至5.26%。
  • 去糖基化单抗32-106显著降低胎儿死亡至2.17%。
  • 免疫雌鼠胎盘存在缺陷,母体抗CD36抗体抑制胎盘内皮细胞血管生成,去糖基化32-106可恢复。

关键数值与推荐

  • IVIG剂量1 g/kg,给药日7、12、17可降低胎儿死亡;延迟至10、15、20则无效。
  • 去糖基化抗CD36多克隆抗体剂量5 mg/kg,给药日10、15、20,胎儿死亡5.26%。
  • 去糖基化单抗32-106显著降低胎儿死亡至2.17%。

临床怎么用

  • 动物模型提示产前IVIG或去糖基化抗CD36抗体可能治疗抗CD36介导的FNAIT。
  • 去糖基化单抗32-106因更低剂量、更晚起始和更高成功率,可能更具临床开发潜力。

局限性

  • 研究为小鼠模型,结果需在人类中进一步验证。
  • 样本量、统计P值等未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent studies have shown that maternal anti-CD36 antibodies represent a frequent cause of fetal/neonatal alloimmune thrombocytopenia (FNAIT) in Asian and African populations. However, little is known about the pathomechanism and antenatal treatment of anti-CD36-mediated FNAIT. Here, we established a novel animal model to examine the clinical features of pups from immunized Cd36-/- female mice after breeding with wild-type male mice. Mild thrombocytopenia was observed, but high pup mortality was also documented (40.26%). Administration of intravenous immunoglobulin (IVIG) (1 g/kg) on days 7, 12, and 17 to immunized Cd36-/- mothers after breeding reduced fetal death (12.70%). However, delaying the IVIG administration series on days 10, 15, and 20 did not reduce fetal death (40.00%). In contrast, injection of deglycosylated anti-CD36 (deg-anti-CD36) polyclonal antibodies (5 mg/kg) on days 10, 15, and 20 significantly reduced fetal death (5.26%). Subsequently, monoclonal antibodies (mAbs) against mouse CD36 were developed, and one clone producing high-affinity anti-CD36 (termed 32-106) effectively inhibited maternal antibody binding and was therefore selected. Using the same approach of deg-anti-CD36, the administration of deg-32-106 significantly reduced fetal death (2.17%). Furthermore, immunized Cd36-/- mothers exhibited placental deficiency. Accordingly, maternal anti-CD36 antibodies inhibited angiogenesis of placenta endothelial cells, which could be restored by deg-32-106. In summary, maternal anti-CD36 antibodies caused a high frequency of fetal death in our animal model, associated with placental dysfunction. This deleterious effect could be diminished by the antenatal administration of IVIG and deg-mAb 32-106. Interestingly, treatment with deg-32-106 seems more beneficial considering the lower dose, later start of treatment, and therapy success.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Xu X, Chen D, Ye X, et al. Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model. Blood. 2021. PMID: 34041523. doi:10.1182/blood.2021011131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。